Results from the EXCELLA II Randomized Clinical Trial using Elixir Medical’s DESyne Novolimus-Eluting Coronary Stent System to Be Featured In the Late Breaking Clinical Trial Presentation at EuroPCR10

SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of innovative drug eluting stent platforms for the treatment of cardiovascular disease, today announced two key presentations scheduled for the 2010 EuroPCR meeting featuring the company’s cardiovascular innovations.